Literature DB >> 24440499

Activation of TOPK by lipopolysaccharide promotes induction of inducible nitric oxide synthase through NF-κB activity in leukemia cells.

Jung-Hwan Park1, Yu-Jin Jeong1, Hee Kwan Won2, Sang-Yun Choi3, Jong-Hwan Park1, Sang-Muk Oh4.   

Abstract

T-LAK cell-originated protein kinase (TOPK) is known to be involved in tumorigenesis or cancer progression. However, the role of TOPK in inflammatory response remains elusive. Here we show that TOPK positively regulates inducible nitric oxide synthase (iNOS) gene expression and nitric oxide (NO) production in response to lipopolysaccharide (LPS). In TOPK-depleted cells, the iNOS expression was shown to be greatly abolished. Also, we revealed that LPS treatment augmented the expression and activity of TOPK, the interaction of TOPK with IκBα, and promoted TOPK kinase activity against IκBα. Moreover, NF-κB or iNOS promoter-driven transcriptional activity in response to LPS was markedly reduced by knocking down of TOPK or deletion of NF-κB sites. On the other hand, endogenous TOPK level was expressed very lowly in bone marrow-derived macrophage (BMDM) prepared from Toll-like receptor 4 (TLR4) knockout mice, compared to BMDM from wild type (WT) mice. Collectively, these findings demonstrate that TOPK upregulates iNOS gene expression in T cell leukemia Jurkat cells or macrophage leukemic Raw 264.7 cells via NF-κB activation in response to LPS, and might act as a critical effector in LPS/TLR4-mediated signaling cascade, suggesting a possible role of TOPK in inflammatory response or inflammation-related diseases.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inflammation; NF-κB; TOPK; iNOS

Mesh:

Substances:

Year:  2014        PMID: 24440499     DOI: 10.1016/j.cellsig.2014.01.004

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  17 in total

1.  Identification of the oncogenic kinase TOPK/PBK as a master mitotic regulator of C2H2 zinc finger proteins.

Authors:  Raed Rizkallah; Paratchata Batsomboon; Gregory B Dudley; Myra M Hurt
Journal:  Oncotarget       Date:  2015-01-30

2.  'Preconditioning' with low dose lipopolysaccharide aggravates the organ injury / dysfunction caused by hemorrhagic shock in rats.

Authors:  Regina Sordi; Fausto Chiazza; Nimesh S A Patel; Rachel A Doyle; Massimo Collino; Christoph Thiemermann
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

3.  Cefradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of T-LAK cell-originated protein kinase.

Authors:  Xiaoming Fan; Qiuhong Duan; Changshu Ke; Guiping Zhang; Juanjuan Xiao; Dan Wu; Xiaoyu Zeng; Jingwen Chen; Jinguang Guo; Jie Zhou; Fei Shi; Feng Zhu
Journal:  Oncotarget       Date:  2016-04-26

4.  Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase.

Authors:  Jianjun Yang; Donghong Yuan; Tongchao Xing; Hongli Su; Shengjun Zhang; Jiansheng Wen; Qiqiang Bai; Dongmei Dang
Journal:  J Ginseng Res       Date:  2016-04-05       Impact factor: 6.060

5.  Identification of potential key genes associated with glioblastoma based on the gene expression profile.

Authors:  Lijuan Bo; Bo Wei; Chaohui Li; Zhanfeng Wang; Zheng Gao; Zhuang Miao
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

6.  Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase.

Authors:  Mengzhu Zheng; Shanshan Luan; Suyu Gao; Li Cheng; Bin Hao; Jiacheng Li; Yao Chen; Xuemei Hou; Lixia Chen; Hua Li
Journal:  Oncotarget       Date:  2017-06-13

7.  Role of TOPK in lipopolysaccharide-induced breast cancer cell migration and invasion.

Authors:  Min-Ah Seol; Jung-Hwan Park; Ji Heun Jeong; Jungmook Lyu; Seung Yun Han; Sang-Muk Oh
Journal:  Oncotarget       Date:  2017-06-20

Review 8.  PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Authors:  Hai Huang; Mee-Hyun Lee; Kangdong Liu; Zigang Dong; Zeayoung Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

9.  TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.

Authors:  Ying Li; Zhiwei Yang; Weijie Li; Shudi Xu; Tao Wang; Ting Wang; Mengjie Niu; Shengli Zhang; Lintao Jia; Shengqing Li
Journal:  Oncotarget       Date:  2016-02-09

10.  TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.

Authors:  Giacomo Pirovano; Thomas M Ashton; Katharine J Herbert; Richard J Bryant; Clare L Verrill; Lucia Cerundolo; Francesca M Buffa; Remko Prevo; Iona Harrap; Anderson J Ryan; Valentine Macaulay; William G McKenna; Geoff S Higgins
Journal:  Br J Cancer       Date:  2017-07-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.